Ovarian cancer mortality rates have not decreased significantly in the past years. As most women are still diagnosed in an advanced stage, there is a need for new treatment strategies for recurrent disease. A potentially new developing targeted approach, theranostics, combines diagnostics and treatment using radiopharmaceuticals. Through target receptors, imaging and treatment of malignant tissue can be achieved. For ovarian malignancy, the follicle-stimulating hormone (FSH) receptor may serve as a possible target since expression appears to be limited to ovarian cells. In this systematic review, we aim to gather all available literature on the expression of the FSH receptor in ovarian tumors. Pubmed, Embase and the Cochrane databases were searched until December 2023 for eligible studies. The search yielded 41 studies, mostly regarding serous carcinomas, sex cord–stromal tumors (SCSTs) and cell lines of serous and SCSTs. Various techniques were used to analyze the expression of the FSH receptor. For serous carcinomas, conflicting results on the expression of the FSH receptor were found. Studies on SCSTs, mainly studying the subtype of granulosa cell tumors, all showed positive expression of the FSH receptor. In the cell lines studies, the KGN cell line derived from a granulosa cell tumor shows positive expression in all studies. Available studies show that SCSTs express the FSH receptor. A theranostic approach targeting the FSH receptor may, therefore, provide a useful new approach for this malignancy with limited therapeutic options in recurrent disease.
近年来卵巢癌死亡率并未显著下降。由于多数患者确诊时已处于晚期，亟需针对复发性疾病开发新的治疗策略。诊疗一体化作为一种新兴的靶向治疗策略，通过放射性药物实现诊断与治疗的结合。该技术借助靶向受体可实现对恶性组织的显像与治疗。对于卵巢恶性肿瘤，促卵泡激素受体因其表达可能局限于卵巢细胞而成为潜在靶点。本系统性综述旨在汇总所有关于FSH受体在卵巢肿瘤中表达的相关文献。通过检索截至2023年12月的Pubmed、Embase和Cochrane数据库，共纳入41项研究，主要涉及浆液性癌、性索-间质肿瘤及其细胞系。研究采用多种技术分析FSH受体表达情况：浆液性癌中FSH受体表达的研究结果存在矛盾；性索-间质肿瘤（主要针对颗粒细胞瘤亚型）研究均显示FSH受体阳性表达；在细胞系研究中，所有研究均证实颗粒细胞瘤来源的KGN细胞系呈阳性表达。现有研究表明性索-间质肿瘤表达FSH受体，因此针对该受体的诊疗一体化策略可能为治疗选择有限的复发性卵巢恶性肿瘤提供新的有效途径。
肿瘤(癌症)患者之家